Business Description
TTY Biopharm Co Ltd
NAICS : 325412
SIC : 2834
ISIN : TW0004105002
Share Class Description:
ROCO:4105: Ordinary SharesDescription
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.22 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.38 | |||||
| Debt-to-EBITDA | 1.42 | |||||
| Interest Coverage | 35.78 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.46 | |||||
| Beneish M-Score | -2.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.3 | |||||
| 3-Year EBITDA Growth Rate | 6.3 | |||||
| 3-Year EPS without NRI Growth Rate | 6.9 | |||||
| 3-Year FCF Growth Rate | 42 | |||||
| 3-Year Book Growth Rate | 2.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.72 | |||||
| 9-Day RSI | 71.57 | |||||
| 14-Day RSI | 67.63 | |||||
| 6-1 Month Momentum % | -5.54 | |||||
| 12-1 Month Momentum % | -11.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.77 | |||||
| Quick Ratio | 1.33 | |||||
| Cash Ratio | 0.87 | |||||
| Days Inventory | 183.69 | |||||
| Days Sales Outstanding | 80.05 | |||||
| Days Payable | 28.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.64 | |||||
| Dividend Payout Ratio | 0.78 | |||||
| 3-Year Dividend Growth Rate | -5.3 | |||||
| Forward Dividend Yield % | 4.64 | |||||
| 5-Year Yield-on-Cost % | 3.2 | |||||
| Shareholder Yield % | 4.58 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.47 | |||||
| Operating Margin % | 23.04 | |||||
| Net Margin % | 19.22 | |||||
| FCF Margin % | 17.45 | |||||
| ROE % | 19.13 | |||||
| ROA % | 11.02 | |||||
| ROIC % | 16.62 | |||||
| ROC (Joel Greenblatt) % | 39.72 | |||||
| ROCE % | 20.62 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.8 | |||||
| Forward PE Ratio | 16.56 | |||||
| PE Ratio without NRI | 16.93 | |||||
| Shiller PE Ratio | 12.93 | |||||
| Price-to-Owner-Earnings | 18.63 | |||||
| PS Ratio | 3.22 | |||||
| PB Ratio | 3.02 | |||||
| Price-to-Tangible-Book | 3.22 | |||||
| Price-to-Free-Cash-Flow | 18.49 | |||||
| Price-to-Operating-Cash-Flow | 16.78 | |||||
| EV-to-EBIT | 12.33 | |||||
| EV-to-Forward-EBIT | 13.56 | |||||
| EV-to-EBITDA | 10.88 | |||||
| EV-to-Forward-EBITDA | 12.1 | |||||
| EV-to-Revenue | 3.13 | |||||
| EV-to-Forward-Revenue | 3.28 | |||||
| EV-to-FCF | 17.27 | |||||
| Price-to-Projected-FCF | 1.24 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.46 | |||||
| Price-to-Graham-Number | 1.56 | |||||
| Price-to-Net-Current-Asset-Value | 13.13 | |||||
| Earnings Yield (Greenblatt) % | 8.12 | |||||
| FCF Yield % | 5.43 | |||||
| Forward Rate of Return (Yacktman) % | 11.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TTY Biopharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 5,826.487 | ||
| EPS (TTM) (NT$) | 4.5 | ||
| Beta | -0.12 | ||
| Volatility % | 12.12 | ||
| 14-Day RSI | 67.63 | ||
| 14-Day ATR (NT$) | 0.674848 | ||
| 20-Day SMA (NT$) | 73.815 | ||
| 12-1 Month Momentum % | -11.79 | ||
| 52-Week Range (NT$) | 69.5 - 83.6 | ||
| Shares Outstanding (Mil) | 248.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TTY Biopharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TTY Biopharm Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TTY Biopharm Co Ltd Frequently Asked Questions
What is TTY Biopharm Co Ltd(ROCO:4105)'s stock price today?
The current price of ROCO:4105 is NT$75.60. The 52 week high of ROCO:4105 is NT$83.60 and 52 week low is NT$69.50.
When is next earnings date of TTY Biopharm Co Ltd(ROCO:4105)?
The next earnings date of TTY Biopharm Co Ltd(ROCO:4105) is .
Does TTY Biopharm Co Ltd(ROCO:4105) pay dividends? If so, how much?
The Dividend Yield %  of TTY Biopharm Co Ltd(ROCO:4105) is 4.64% (As of Today), Highest Dividend Payout Ratio of TTY Biopharm Co Ltd(ROCO:4105) was 1.25. The lowest was 0.51. And the median was 0.74. The  Forward Dividend Yield % of TTY Biopharm Co Ltd(ROCO:4105) is 4.64%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers